Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. - Wikidata - awgldk - TriplyDB

Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.

Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.

http://www.wikidata.org/entity/Q38970639

about

Hepatitis C: a review for primary care physicians Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4 Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians The Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon Therapy Enhancing our understanding of current therapies for hepatitis C virus (HCV)The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage.Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin.Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis.Does HCV Patients Who Have BCL2 43Ala Genotype and Normal GH1 Levels Can Achieve Response to IFN Based Therapy?Management of chronic hepatitis C: consensus guidelines.Chronic hepatitis C virus infection: genotyping and its clinical role.Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: A systematic review and meta-analysis.Role of different regions of the hepatitis C virus genome in the therapeutic response to interferon-based treatment.Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues.Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.Characterization of full-length hepatitis C virus genotype 4 sequences.Clinical and pathological characteristics and response to combination therapy of genotype 4 chronic hepatitis C patients: experience from a spanish center.Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting.Challenge of hepatitis C in Egypt and hepatitis B in Mauritania

P2860

Q22306040-66297F5A-9905-4410-89C4-DFB58861D6A7 Q24200189-445F3C8B-9B9C-4776-A3E6-795FAB3E328E Q27478102-3E93A9E6-9F62-4787-9510-FE4B2CC24F40 Q27488260-619A8234-337F-40AF-8A1A-6BADACA5E45A Q27489040-06A24116-04D1-4B09-8A6D-7466B409E645 Q28085718-69D94798-8B57-4587-A39B-0FF1BCCCEEB7 Q28550281-B4BB36EE-BE32-444D-9E8D-00E63DEDAE66 Q33869261-4EB8672B-6134-410E-A82E-1ABF3FA60903 Q34270336-CE64FBDF-F23E-4810-93A5-4E30C1FCBCA9 Q34286532-8686A7CA-E36C-44D2-86E4-8FCC9ACE49C4 Q34387913-1B101B53-67B1-44CA-9399-56997B9A2E38 Q36140466-5CCBAB8C-D361-4853-B6B0-8C4E9EE7006F Q36336416-958EDE96-2011-4F0C-AE5B-4A81435BB248 Q36849347-0EF4A10F-ACF0-45A7-B478-4DBBD2853C87 Q36895749-169EF3F4-CB12-47DC-A6BF-47A43AF17BBB Q37724686-B2ABC3E3-191D-4A6B-884A-3B8858468866 Q38086264-7FB02983-BCD0-48C9-A0CD-86F600B35D99 Q38121422-AB1B1F9A-567C-461E-AD7A-E5E02D3B5861 Q38174246-2ED6A580-4D2B-4F06-8304-B2278617C8F0 Q38224436-4007022F-72CF-4949-ACD5-401B43E06DA8 Q43037234-5EF387B1-88CA-4553-8E8E-B2DAE157DBEF Q43040692-41B897F6-24F2-4B93-968D-AA006D63E125 Q55263598-82059938-AA78-413C-B3AC-6FD9C7A11AE6 Q57491236-857C05C0-6ECC-40AB-A472-BCB879A09007

P2860

Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.

http://www.wikidata.org/entity/Q38970639

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Pegylated interferon-alpha 2b- ...... genotype 4 chronic hepatitis.

@en

type

label

Pegylated interferon-alpha 2b- ...... genotype 4 chronic hepatitis.

@en

prefLabel

Pegylated interferon-alpha 2b- ...... genotype 4 chronic hepatitis.

@en

P1433

Q38970639-6B3F42DD-47AE-4A03-9AEE-17592CA935B1

P1476

Q38970639-353D5C65-BA91-4CE8-AEDE-AA3D9D780ECA

P2093

Q38970639-32A0B333-D38F-4752-B8E5-D34457B10D7F

Q38970639-474C949A-78C5-440B-BBDC-5F06EC63BA59

Q38970639-63FA9ED7-D518-4FA9-8624-CE342D0E0B73

Q38970639-7720AAC9-F83F-4F8A-9DAC-00D4BF6B66E7

Q38970639-863425BC-0D62-410D-A45A-4F5F7B273090

Q38970639-BBDCE887-4558-4844-A267-563B92143A1E

P2860

Q38970639-2C6A33DB-3F91-4FD7-985B-17F9A00F70B2

Q38970639-386BECE5-4117-4786-A4BD-46576960D54C

Q38970639-543CC2A4-DDB5-4E64-A118-CC84247F5B94

Q38970639-5505CF05-E0AB-479C-91AA-3FA49D74533C

Q38970639-5FBDA942-ED31-45A8-A7A0-9E77EAEE393D

Q38970639-7D9CC6EF-763B-430B-A8FB-9F3A1B7101E3

Q38970639-84363BB9-8F25-4EB9-836B-2F7E665A1222

Q38970639-873EE745-AE2A-4CCF-856D-7D76834F40DD

Q38970639-9E92BB98-A27B-47F1-920A-095A3535EA73

Q38970639-BD7A6F88-E7B1-4A67-A4CE-7A047527159A

P304

Q38970639-B7B77E10-5945-4A61-8016-6D448A073730

P31

Q38970639-DEDF985C-A453-4E34-8A39-33940111C308

P356

Q38970639-E79F5A74-B333-4BBD-9ABF-B6031347AC75

P433

Q38970639-4ED506B2-A960-4D04-8CC3-BF077B210617

P478

Q38970639-C992B116-CF28-4030-8511-1E1C717B7737

P577

Q38970639-C32CBD00-EB52-4A49-8661-8D184B3E1249

P698

Q38970639-60996FEC-E38D-4C77-81E5-FE25CA34BE30

P356

J.1365-2893.2005.00604.X

P1433

Journal of Viral Hepatitis

P1476

Pegylated interferon-alpha 2b- ...... genotype 4 chronic hepatitis.

@en

P2093

A Amer

http://www.w3.org/2001/XMLSchema#string

A Bener

http://www.w3.org/2001/XMLSchema#string

A C Lopez

http://www.w3.org/2001/XMLSchema#string

M Derbala

http://www.w3.org/2001/XMLSchema#string

M El Ghannam

http://www.w3.org/2001/XMLSchema#string

M Omar

http://www.w3.org/2001/XMLSchema#string

P2860

Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt.

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt.

Genotype and viral load as prognostic indicators in the treatment of hepatitis C.

Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection.

Hepatitis C: an epidemiological review.

Pegylated interferons for the treatment of chronic hepatitis C infection.

HCV infection in Egyptian patients with acute hepatitis.

Hepatitis C virus genotyping versus serotyping in Egyptian patients.

P304

380-385

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2893.2005.00604.X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2005-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15985008

http://www.w3.org/2001/XMLSchema#string